Pharmidex attending the Global Business Accelerator visit to Switzerland

March 10, 2018

Pharmidex will be attending the Global Business Accelerator Program which is run by the Enterprise Europe Network and supported by Innovate UK.

The Enterprise Europe Network, supported by Innovate UK, are visiting Switzerland to focus on the pharmaceutical technology industry. The chosen companies will have the opportunity to meet pharmaceutical companies and key stakeholders based in Basel and attend ProcureCon Pharma in Zürich for the next three days

The Swiss pharmaceutical sector is a major employer with more than 40,000 people working directly for the industry. If the indirect work created through ancillary industries is included, as many as 172,000 jobs are related to the pharmaceutical industry. In addition, it accounts for up to a third of all Swiss exports, and the productivity of the industry is four times as high as that of the economy as a whole.

Three big clusters – the Lake Geneva area, the Basel region and Zürich-Zug-Lucerne – account for the lion’s share of the gross value added of the Swiss pharmaceutical industry and present many collabartive opputunities for UK companies.

During the trip Pharmidex will also be attending ProcureCon Pharma, organised by Worldwide Business Research, will take place from 13 to 15 March 2018 in Zürich. Delegates will have the opportunity to join 200 senior procurement professionals from Merck, Astra Zeneca, Roche, Sanofi, Lonza and other world-leading pharmaceutical businesses over three days.

We look forward to meeting you there.

< Older Post

Newer Post >

Advancing Preclinical Respiratory Research with Plethysmography

April 9, 2026

Pharmidex partners with Data Sciences International (DSI) to utilise industry-leading whole body plethysmography (WBP) systems, incorporating the patented Halcyon® pneumotach noise suppression technology. This enables the delivery of high-quality preclinical respiratory studies with enhanced clarity, sensitivity and confidence. By leveraging the robustness of DSI’s WBP platform alongside Pharmidex’s scientific expertise, we offer well-characterised models to assess: • Cough responses • Hypercapnic challenge responses • Functional respiratory changes across disease states such as asthma This integrated approach supports reliable and translatable assessment of airway function, disease progression and therapeutic efficacy, helping to de-risk programmes and drive better decision-making in preclinical development. Always keen to hear how others are advancing respiratory endpoints in their studies.

Pharmidex is now a partner in the European Innovation Council

April 1, 2026

We’re pleased to share that Pharmidex has been selected as a partner in the EIC - European Innovation Council Ecosystem Partnership Programme. Our services are now featured on the EIC Service Catalogue, making them accessible to innovative companies and projects supported by the EIC across Europe. This is a great opportunity to further support cutting-edge biotech and life sciences programmes by providing: 🔬 Preclinical in vivo pharmacology 🧪 Bioanalysis (LC–MS/MS, qPCR, ELISA) 📊 Translational and mechanistic studies 🧫 Histology and pathology We look forward to working with EIC beneficiaries and contributing to the development of the next generation of therapies. If you are part of the EIC ecosystem and looking for a flexible, science-led CRO partner, we would be delighted to connect.

👏 Congratulations to our collaborators on their recent publications

March 26, 2026

We are delighted to congratulate EpiEndo Pharmaceuticals and the Institute of Pharmaceutical Science, King's College London on the publication of two exciting studies exploring the therapeutic potential of EP395: 📄 “ The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung” published in "Lung" 📄 “Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation” published in "Pulmonary Pharmacology & Therapeutics" These studies provide valuable insights into the role of EP395 in modulating inflammatory responses in respiratory disease, supporting its potential as a novel therapeutic approach. At Pharmidex , we are proud to have contributed to this work through our Respiratory Department, supporting the in vivo studies and helping advance these important findings. We look forward to continuing our collaboration and supporting innovative programmes in respiratory drug discovery and development.